17 abr 2018 ano - FDA is hosting a public meeting on Patient- Focused Drug Development for Opioid Use Disorder (OUD), in collaboration with National Institute of Drug Abuse (NIDA). In addition to NIDA, FDA is also working closely with patient advocacy and community organizations to encourage participation from individuals with OUD. This meeting aligns with FDA’s ongoing work aimed at reducing the impact of opioid abuse and addiction.

Adicionado na linha do tempo:

Opioids and the FDA

ByAnastasia

13 nov 2018

0

0

520

Data: